| Center (observation period, type of study) | Sub-group main characteristics* | No. of patients* | Treatment regimen | Median FUP (range) | Local Control | Overall Survival | Main Toxicity** |
| PMRC (1985-2006, R) | HCC >10 cm in maximal dimension | 22 | 47 - 89.1 Gy in 10 - 35 f | 13.4 m (1.5 - 85) | 87% at 2 y | 36% at 2 y | 3 liver failures with no evidence of HCC |
| PMRC (1989-2000, R) | Pts receiving >1 course of PT | 27 (68 T) | 1st course: median dose = 72 Gy in 16 f, other courses median dose = 66 Gy in 16 f | 62.2 m (8.6 - 148.5) | 87.8% at 5 y | 55.6% at 5 y | 2 acute liver failures2 late bile duct stenoses |
| PMRC (1990-2000, R) | Pts unfit to receive other treatment modalities*** due to coexisting diseases | 21 | 63 - 84 Gy in 13 - 27 f | 3.3 y (0.3 - 10.7 y) | 93% at 5 y | 33% at 5 y | No ≥ G3 toxicities |
| PMRC (1990-2000, R) | Pts with deteriorated liver function (CP C) | 19 | 50 - 84 Gy in 10 - 24 f of 3 - 5 Gy | 17 m (3 - 63) | 91% at 17 m | 42% at 2 y | No ≥ G3 toxicities No worsening of CP score |
| PMRC (1991-2005, R) | Pts with PVTT | 35 | 55 - 77 Gy in 10 - 35 f of 2.2 - 5 Gy delivered to PVTT ± primary HCC | 21 m (2 - 88) | 91% at 2 y | 48% at 2 y 21% at 5 y | 1 transient late duodenal bleeding, 1 G4 thrombocytopenia |
| PMRC (2001-2007, R) | Pts with HCC located adjacent to the alimentary tract ( within 2 cm) | 47 | 16 pts receiving 72.6 Gy in 22 f, 31 pts receiving 77Gy in 35 f. PTV reduced after 10 - 25 f to avoid excess radiation to the alimentary tract | 23 m (2.8 - 52.4) | 88.1% at 4 y | 34.3% at 4 y | 4 ≥ G2 GI toxicities (1surgical intervention required) |
| PMRC (2002-2004, R) | Pts with HCC located adjacent to PH | 52 | 72.6 Gy in 22 f (3.3 Gy/f) | Not reported | 86% at 3 y | 45.1% at 3 y 83.9% at 3 y for solitary T, CP A pts | 3 G2 skin toxicities |
| PMRC (2001-2006, R) | Aged pts (≥80 y) | 21 | various schedules = 60 Gy in 10 f, 66Gy in 22 f, 70 Gy in 35 f) | Not reported | 100% at 3 y | OS = 62% at 3 y CSS = 70% at 3y | 2 G3 thrombocytopenia |
| PMRC (2001-2004, R) | Pts with HCC located ≥2 cm away from GI tract and PH | 51 | 66 Gy in 10 f | 34 m (1 - 76) | 87.8% at 5 y | OS = 38.7% at 5 y CSS = 60.1 at 5 y | No RILD, 3 late rib fractures |
| PMRC (2001-2007, R) | 3 group of pts = (1) peripheral tumors, (2) tumors located near GI tract and (3) tumors near PH | (1) = 104 (2) = 60 (3) = 95 | 66 Gy in 10 f 77 Gy in 35 f 72.6 Gy in 22 f 7 pts =>1 protocol | Not reported | 81% at 5 y (overall) | OS = 48% at 5y PFS = 12% at 5y (overall) | 2 G3 acute dermatitis 3 rib fractures 1 G3 late dermatitis 3G3 late GI toxicities |
| PMRC (1985-1998, R) | Review of all patients treated in the observation period | 162 | Various schedules = 72 Gy in 16 f, 78 Gy in 20 f, 84 Gy in 24 f, 50 Gy in 10 f | 31.7 m (3.1 - 133.2) | 86.9% at 5 y for all T | 23.5% at 5 y 53.5% at 5 y for CP A and single T | Acute toxicity: 9.7% ↑ transaminase level (autoresolving) Late toxicity: 1.1% Infection biloma 0.5% Biliary duct stenosis 1.1% GI bleeding |
| PMRC (2001-2007, R) | Review of all patients treated in the observation period | 318 | Various schedules = 77 Gy in 35 f, 72, 6 Gy in 22 f, 66 Gy in 10 f | 19.3 m (1.2 - 63.6) | 83.3% at 5 y for peripheral, single T. | 44.6% at 5 y for all pts (55.9% at 5y CP A pts, 44.9% CP B pts) P < 0.01 | 3 (1.2%) G2 GI 1 pt G3 GI (→surgery) 3 rib fractures 28 G2 skin toxicities |